Belimumab (Benlysta®)

Assessment Status Rapid Review complete
Drug Belimumab
Brand Benlysta®
Indication As add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.
Assessment Process
Rapid review commissioned 11/08/2011
Rapid review completed 31/08/2011
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended

Not considered cost-effective due to non-submission of full pharmacoeconomic evaluation.